A Phase III double-blind placebo-controlled Randomised Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502324-48-00

Acronym

NL38132.058.14

Enrollment

1588

Registered

2023-02-13

Start date

2014-08-05

Completion date

Unknown

Last updated

2023-02-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with resected colon carcinoma

Brief summary

5 year Overall Survival (5y-OS)

Detailed description

Disease Free Survival (DFS), Time to Treatment Failure (TTF)

Interventions

DRUGACETYLSALICYLIC ACID

DRUGPLACEBO

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
5 year Overall Survival (5y-OS)	—

Secondary

Measure	Time frame
Disease Free Survival (DFS), Time to Treatment Failure (TTF)	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026